<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03701113</url>
  </required_header>
  <id_info>
    <org_study_id>2018_04_05_EHS</org_study_id>
    <nct_id>NCT03701113</nct_id>
  </id_info>
  <brief_title>Milk Protein and Bone Health in Postmenopausal Women</brief_title>
  <acronym>OSTEOMILK</acronym>
  <official_title>Evaluation of a Milk-Based Protein Supplement to Effect a Positive Change in Bone Health in Post-Menopausal Women Aged 50 to 70 y at Risk of Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Limerick</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Dairygold Cooperative Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Limerick</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The process of bone remodeling exhibits pronounced diurnal pattern that is important for bone
      health. A balanced rate of bone resorption is required to maintain bone health, a balance
      that can be disturbed during the life-cycle to effect net rate of formation (as occurs during
      growth and development to adulthood) or net resorption (as occurs, for example, during the
      menopause). Bone turnover is a nutritionally modulated process and the investigators believe
      a milk-based protein supplement (MBPS) can modulate beneficially the rate of bone resorption
      over the time period when bone remodeling is most active i.e. late evening/overnight. In this
      novel approach to the timing of nutrient ingestion, the proposed nutrient intervention seeks
      to modify (reduce) the rate of bone resorption and promote the rate of bone formation to the
      benefit of bone health in this at risk population..
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design:

      A block randomised, controlled study among healthy, post-menopausal women with osteopenia
      receiving a milk-based protein supplement (MBPS) in the evening, or not,(CONTROL) for a
      period of 24 weeks.

      Composition of MBPM - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with
      40ug Vit D flavoured and textured. All formulations to be supplied food grade and product
      tested by Dairygold Co-operative Society, Mitchelstown, Ireland.

      Participants:

      60 Post-menopausal women with osteopenia as determined by site-specific bone mineral density
      BMD (DXA) diagnosed and screened by a clinician and for dietary intake of calcium and Vit D
      by a clinical dietitian.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 22, 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A block randomised, controlled study among healthy, post-menopausal women with osteopenia receiving a milk-based protein supplement (MBPS) in the evening, or not (CONTROL), for a period of 24 weeks.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Aerial Bone Mineral Density (BMD)</measure>
    <time_frame>Change from Baseline BMD at 24 weeks</time_frame>
    <description>Site specific (hip and lumbar) BMD measured by Dual Energy X-ray Absorptiometry (DXA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bone Resorption</measure>
    <time_frame>Change from Baseline CTX, NTX and DPD at 24 weeks</time_frame>
    <description>Measured by biomarkers of bone resorption in fasting blood, i.e. C-terminal telopeptide of type I collagen (CTX, ng/ml), and diurnal (24h) urinary deoxypyridinoline (DPD, nmol/mmol creatinine) and N-terminal telopeptide of type I collagen (NTX, nmol/mmol creatinine) excretion normalised for urinary creatinine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Formation</measure>
    <time_frame>Change from Baseline P1NP at 24 weeks</time_frame>
    <description>Measured by a biomarker of bone formation in fasting blood, i.e. serum pro-collagen type 1 N-terminal propeptide (P1NP, ng/ml)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bone and Bones</condition>
  <condition>Osteoporosis Risk</condition>
  <condition>Osteoporosis, Postmenopausal</condition>
  <arm_group>
    <arm_group_label>Milk-based protein matrix (MBPM)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Dietary Supplement : Test Product Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover Composition of Test Product - 25g of milk-based proteins + 1000mg dairy-based calcium fortified with 40ug Vit D flavoured and textured supplied food grade and product tested by Dairygold Co-operative Society, Mitchelstown, Ireland.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention: Habitual dietary behaviour Intervention: Diagnostic Test : Aerial Bone Mineral Density (BMD) Intervention: Diagnostic Test : Bone Turnover</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Milk-based protein matrix (MBPM)</intervention_name>
    <description>Ingestion of the Test Product at 10:00 pm, post-absorptive of the evening meal, each day for the 24 week period of intervention</description>
    <arm_group_label>Milk-based protein matrix (MBPM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Habitual dietary behaviour</intervention_name>
    <description>Subjects to maintain habitual dietary behaviour for the 24 week intervention</description>
    <arm_group_label>CONTROL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Post-menopausal women aged 50-70y. Assessed by site-specific BMD to be osteopenic.
             Assessed by clinical screen to be otherwise healthy and free from other illness or
             current medication likely to influence the study outcome.

        Exclusion Criteria:

          -  Intolerance to dairy-based food products
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip M Jakeman, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Limerick</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philip M Jakeman, PhD</last_name>
    <phone>+35361202800</phone>
    <phone_ext>2800</phone_ext>
    <email>phil.jakeman@ul.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Clarke-Moloney, BSc</last_name>
    <phone>+35361204230</phone>
    <phone_ext>4230</phone_ext>
    <email>mary.clarke-moloney@ul.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Limerick</name>
      <address>
        <city>Limerick</city>
        <zip>V94 T9PX</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philip M Jakeman, PhD</last_name>
      <phone>+35361202800</phone>
      <phone_ext>2800</phone_ext>
      <email>phil.jakeman@ul.ie</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Norton, PhD</last_name>
      <phone>+35361204780</phone>
      <email>catherine.norton@ul.ie</email>
    </contact_backup>
    <investigator>
      <last_name>Philip M Jakeman, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Norton, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <link>
    <url>http://ul.ie./4i</url>
    <description>Center for Interventions in Inflammation Infection and Immunity</description>
  </link>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>October 5, 2018</last_update_submitted>
  <last_update_submitted_qc>October 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Bone Turnover Markers</keyword>
  <keyword>Dairy Products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>2018_04_05_EHS</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>http://www.ul.ie/ehs/research-ethics</doc_url>
      <doc_comment>Contact The EHS Research Ethics Contact Point of the Education and Health Sciences Research Ethics Committee, Room E1003, University of Limerick, Limerick, Ireland</doc_comment>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03701113/Prot_ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/13/NCT03701113/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

